Abstract: The analysis method includes a step of measuring cytometry parameters for each biological cell contained in a biological sample; a step of determining, for each biological cell of the biological sample, a point in a N-dimensional space whose coordinates are defined depending on the cytometry parameters measured for the corresponding biological cell, where N is an integer greater than or equal to 3; a step of automatic clustering of the points into different cell clusters depending on the measured cytometry parameters, so as to define a sample cluster file; and a step of comparing the sample cluster files with reference cluster files, each of the reference cluster files being defined from cytometry parameters of a respective pathological or abnormal biological sample.

Abstract: Disclosed is a device for packaging balls for reaction vessels for an analysis appliance, including: a body including at least one opening and used to house balls, a closing member, that can be moved relative to the body between a closed position in which the closing member closes the opening of the body, and an open position in which the opening of the body is open so as to allow the balls to be dispensed from the body.

Abstract: The present invention relates to a universal calibration method of use for assaying inhibitors of the same enzyme, for example for assaying inhibitors of an enzyme of blood coagulation. The invention also relates to the use of this universal calibration in a method for assaying a reversible or irreversible inhibitor of the enzyme in a biological sample. The invention also relates to the use of the universal calibration in a method for screening inhibitors of the enzyme.

Abstract: Double bag having a first compartment containing a composition to be distributed and a second compartment for receiving a used fluid, a first bag connector communicating with the first compartment and serving to empty the latter, and a second bag connector communicating with the second compartment and serving to fill the latter.

Abstract: Disclosed is a gripping device for a container intended for a biological analysis, including an annular part of X axis, elastically deformable gripping fins extending radially inwardly from the annular part, the fins being capable of being deformed when a container is introduced into the annular part, the fins being evenly distributed over the circumference. Each fin has a so-called upper surface and an opposite so-called lower surface, the lower surface being intended to come into contact with the container, the lower surface having a concave zone, or vice versa.

Abstract: This determination method comprises the steps consisting of providing a reaction vessel (2) containing a blood sample (33) and a ferromagnetic ball (11) placed on a raceway (9) provided in the bottom of the reaction vessel (2), subjecting the ball (11) to a magnetic field so as to move the ball along the raceway (9) in an oscillatory motion, exposing the blood sample to an incident light beam (36), detecting a light beam (38) transmitted through the reaction vessel (2) and coming from the incident light beam (36) in such a way as to provide a measurement signal, carrying out a first processing of the measurement signal in such a way as to provide a first signal representative of the variation of at least one physical quantity representative of the movement of the ball (11), carrying out a second processing of the measurement signal in such a way as to provide a second signal representative of the variation of at least one optical property of the blood sample, determining a first value of the coagulation time

Abstract: The present invention relates to a universal calibration method of use for assaying inhibitors of the same enzyme, for example for assaying inhibitors of an enzyme of blood coagulation. The invention also relates to the use of this universal calibration in a method for assaying a reversible or irreversible inhibitor of the enzyme in a biological sample. The invention also relates to the use of the universal calibration in a method for screening inhibitors of the enzyme.

Abstract: A method of determining the position of at least one fixed cartography token (10) of an automaton, the token (10) including a base (11) having a lateral surface and an end face (14a), a stud (15) of smaller cross section than the base (11) projecting from the end face (14a) of the base (11), the stud (15) including an end face (16) opposite the base (11). The method is aimed in particular at deducing the coordinates (XO, YO, ZO) of at least one point (O) of the cartography token (10) with respect to a movable member.

Abstract: A reaction vessel for an automatic chemical or biological analysis appliance includes a connection part (22) for connection to another vessel (10) of the same type, the connection part is resiliently snap-fastened on the top end of the vessel (10) and is also resiliently snap-fastened to the connection part (22) of another vessel so as to form a string of vessels that are hinged to one another about transverse axes (xx)?.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: A method is provided for adjusting either the signal measured or activity calculated by an instrument or a predefined calibration curve for a medical diagnostic test, performed on an instrument with pre-calibrated reagents. A calibration adjuster for a blood clotting diagnostic test is further provided.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: The invention concerns the field of hemostasis, in particular blood coagulation disorders linked to an abnormal expression of tissue factor, and to physiopathological phenomena correlated with over-expression of the factor. The present invention provides a method for assaying the activity of circulating tissue factor in a biological sample. The method of the invention is carried out in vitro, in particular on a blood sample collected from a patient.

Abstract: A reaction vessel for an automatic chemical or biological analysis appliance includes a connection part (22) for connection to another vessel (10) of the same type, the connection part is resiliently snap-fastened on the top end of the vessel (10) and is also resiliently snap-fastened to the connection part (22) of another vessel so as to form a string of vessels that are hinged to one another about transverse axes (xx)?.

Abstract: Device for sampling a liquid in a tube by means of a hollow needle (10) passing through the closing cap (12) of the tube (14), means (18, 20) with rack and toothed wheel being provided to oppose the rising of the tube (14) when the needle is extracted from the cap (12).

Abstract: A reaction well, intended for use in an automatic analysis appliance and including an opening at its top end and one or two flaps for partially closing said opening, the flaps being separated by a slot enabling a liquid injection or sampling needle to pass through, and preventing stirrer means contained within the well from escaping.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: A method for the in vitro measurement of the thromboduline functional activity, includes dosing in a biological medium, and from a biological sample, the thrombine-activation of C protein into activated C protein (PCa) in the presence of its co-factor or the thromboduline, the method including adding to the sample plasma the agents necessary for activating the C protein system, adding purified C protein and also adding a fibrin polymerisation inhibitor. Also described is application of the method in the detection of coagulation pathologies.

Abstract: The invention concerns the field of hemostasis, in particular blood coagulation disorders linked to an abnormal expression of tissue factor, and to physiopathological phenomena correlated with over-expression of the factor. The present invention provides a method for assaying the activity of circulating tissue factor in a biological sample. The method of the invention is carried out in vitro, in particular on a blood sample collected from a patient.

Abstract: A method for adjusting the coagulation time during the manufacture of calibrators and controls produced from frozen plasma or plasma treated for lyophilization thereof, for haemostatis tests relating to assaying and to monitoring anticoagulant treatments in a patient. The plasmas selected to prepare the calibrator plasmas or the control plasmas are treated with a view to lyophilization and supplemented with different predefined doses of a drug and a procoagulant factor.